Serum markers for breast cancer.

Area of Science:

• Oncology
• Clinical Chemistry
• Biomarker Research

Background:

• Numerous tumor markers and laboratory tests are employed for breast cancer patient follow-up and evaluation.
• Existing markers are insufficient for sensitive early diagnosis and screening.
• Current markers are valuable for assessing therapy response and detecting relapse.

Purpose of the Study:

• To evaluate the utility of available tumor markers in breast cancer management.
• To compare the sensitivity and specificity of commonly used markers like CA 15-3 and CEA.
• To explore the potential of newer breast mucin-related assays.

Main Methods:

• Analysis of sensitivity and specificity data for CA 15-3 and CEA assays.
• Assessment of combined marker usage for improved detection rates.
• Review of newer breast mucin assays (MCA, MSA, CA 549, CA M26, CA M29, BCM) and their correlation with CA 15-3.

Main Results:

• CA 15-3 and CEA are the most frequently used markers, with CA 15-3 showing slightly higher sensitivity.
• At 97.5% specificity, sensitivity is low for local disease (5-25%) and moderate for advanced disease (50-70%).
• Combined marker use increases sensitivity by 5-10%; newer mucin assays correlate with CA 15-3 but show no superiority.
• 20-30% of advanced cancer patients are negative for these markers, suggesting the need for alternative markers.

Conclusions:

• CA 15-3 and CEA are useful for monitoring breast cancer treatment and relapse but not for early detection.
• No currently available marker is sufficiently sensitive for widespread screening.
• Further research into alternative markers is warranted for patients who are negative for established markers.